Last reviewed · How we verify
NCT06818656
The Unhide™ Project: Economic Impact Study of IVIG Treatment for PANS
trial in PANDAS in 65 participants. Completed in 19 June 2025.
19 June 2025
Quick facts
| Lead sponsor | Brain Inflammation Collaborative |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 65 |
| Start date | 1 March 2025 |
| Primary completion | 19 June 2025 |
| Estimated completion | 19 June 2025 |
| Sites | 1 location across United States |
Conditions studied
- PANDAS — all drugs for PANDAS →
- PANS — all drugs for PANS →
- PANS Pediatric Acute-Onset Neuropsychiatric Syndrome — all drugs for PANS Pediatric Acute-Onset Neuropsychiatric Syndrome →
- Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) — all drugs for Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) →
Sponsor
Brain Inflammation Collaborative
Who can join
Adults 2 to 89, any sex, with PANDAS or PANS. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The Economic Impact Study of IVIG treatment for PANS is a part of the Unhide™ Project, which is a research initiative developed by the Brain Inflammation Collaborative. Specifically, the Unhide™ project is a collection of investigations with the overall goal of better understanding the problems with thinking and mood that can sometimes be symptoms of conditions like autoimmune disease, infection-associated chronic conditions like Long COVID, ME/CFS, PANDAS, PANS, and other illnesses. Your contribution to this research will allow us to better describe these symptoms and understand what causes them, how they develop, and how they can best be treated and prevented. This study seeks to assess how PANDAS/PANS affects the financial well-being of families who pursue IVIG treatment, as well as the overall health and quality of life of children with the condition. By gathering data through this survey, we aim to gain important insights into the economic consequences of treating - or not treating - PANS with IVIG, including how it impacts parents' ability to work and children's ability to attend school. Key Eligibility Criteria * Aged 2-89, U.S. resident, fluent in English, and have access to computer and/or smartphone * Suspected or confirmed diagnosis of PANS/PANDAS * Have received IVIG OR have sought and/or been prescribed IVIG but have not received it
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06818656
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for PANDAS
Currently open trials in the same condition.
- NCT04806620 — Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research · recruiting
Other Brain Inflammation Collaborative trials
Trials by the same sponsor.
- NCT04806620 — Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06818656 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Brain Inflammation Collaborative
- Last refreshed: 12 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06818656.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing